Matej Stuhec1,2
Patricia Di Ciano3,4,5,6*- 1Faculty of Medicine, University of Maribor, Maribor, Slovenia
- 2Department of Clinical Pharmacy, Ormoz Psychiatric Hospital, Ormoz, Slovenia
- 3Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, ON, Canada
- 4Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
- 5Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 6Campbell Family Mental Health Research Institute, Toronto, ON, Canada
Editorial on the Research Topic
Case reports in psychopharmacology, volume III
Mental illness can lead to severe disability and may impact quality of life, even leading to suicidal ideation. The problems associated with mental illness may be more pressing now, as the prevalence of these illnesses may have increased during the recent COVID-19 pandemic (1). Thus, there is a growing need to rise to the challenge to treat these illnesses. This is especially true in view of the fact that many of these patients are treatment-resistant (2). In this third volume of our series of case reports, the overarching theme is the treatment of (mental) illnesses with pharmacotherapies. Continuing from our previous two volumes (3, 4), we present diverse reports on various topics. Not only are there papers on novel treatments for mental illnesses, but we also highlight some new indications for established treatments. We also provide some cautionary tales about the use of some established pharmacotherapies.
The past few years seen a surge in interest in using glucagon-like peptide 1 (GLP-1) receptor agonists. Originally marketed for the treatment of Type 2 diabetes, they are now commonly used for weight management. A paper published this year found evidence that semaglutide may be effective in the treatment of alcohol use disorder (AUD) (5). Consistent with this, Hill et al. report on the successful treatment of AUD with dulaglutide, a GLP-1 receptor agonist. Due to a lapse in insurance coverage, the patient had to discontinue dulaglutide, and they relapsed to previous drinking patterns. Together, this evidence suggests that more large-scale studies are needed into determining the efficacy of GLP-1 receptor agonists for the treatment of AUD and potentially other substance use disorders.
Some mental illnesses can be challenging to manage and two papers in this volume provide some hope for novel methods of managing these disorders. For example, major depressive disorder can be difficult to manage, and many patients may lack the treatment they need. In one case report, Stuhec presents a case of successful treatment of depression by a Pharmacist in primary care. This brings hope that the treatment of depression may extend beyond the physician. Pharmacists collaborated with a general practitioner based on the collaborative practice agreement paper, which the patient also signed. Positive treatment outcomes, such as remission, were reported. This report is in line with the recent developments in Slovenia, where clinical pharmacy services are well developed (6). In another report, on schizophrenia, Hudnik et al. present a case highlighting the role of pharmacogenetics in the treatment efficacy of olanzapine (an atypical antipsychotic, with affinity for serotonin 5-HT2A, dopamine D2, histamine H1, muscarinic M1 and adrenergic α1 receptors) in the management of treatment-resistant schizophrenia. In our previous volume of case reports we also present the utility of pharmacogenetics (4). Thus, novel methods of treatment on the horizon may present new hope for those living with mental illnesses that are difficult to treat.
In the present volume, novel treatment strategies are also presented for two less common illnesses, genital disorder/genitopelvis dysesthesia (PGAD/GPD) and Bainbridge-Ropers syndrome. Rong et al. report on a case of persistent PGAD/GPD that was effectively treated with leuprolide, a synthetic gonadotropin-releasing hormone agonist. The patient exhibited an improvement in genital arousal symptoms as well as a decrease in scores on the Beck Anxiety Inventory and Beck Depression Inventory. Geiser et al. present a potential novel treatment for Bainbridge-Ropers syndrome, typically involving symptomatic treatment. In this report, a 28-year-old male demonstrated an almost complete improvement in challenging behavior following treatment with pregabalin, a modulator of the alpha-2-delta subunit of voltage-gated calcium channels.
Finally, two papers present novel uses of two atypical antipsychotics. Swamy et al. present a literature review and case report highlighting the need to monitor and individually tailor dose adjustments of clozapine (an antagonist at D2 dopamine receptors and antagonist at serotonin 5-HT2A receptors) during anti-tuberculosis therapy. This is important because people with schizophrenia are at heightened risk of tuberculosis (7). As well, Goto et al. describe two cases in which aripiprazole (an antagonist at D2 dopamine receptors and antagonist at serotonin 5-HT2A receptors, as well as a partial agonist at serotonin 5-HT1A and 5-HT2C receptors) improved auditory abnormal sensations, where traditional approaches such as antidepressants and supportive therapy were insufficient.
Even established interventions can present with new warnings over time. Yao et al. report on an 18-year-old female who developed recurrent acute myasthenia after taking lithium; this resolved after discontinuation. In another study, Zhou et al. suggest that people may develop a dependence on tiletamine (a non-competitive antagonist of the NMDA receptor), a novel psychoactive substance that has emerged in China as an additive to e-cigarettes. This is important in view of some findings that people with mental illness have greater odds of smoking (8). Finally, even commonly-used drugs can manifest with adverse events, as reported by Ahmed et al., where they present the case of a 58-year-old woman who developed bilateral peripheral oedema after low-dose escitalopram for the treatment of major depressive disorder. Complete remission of the oedema was seen within three days.
In sum, this Research Topic presents hope for new treatments of illnesses that can be difficult to manage. Even though great improvement in symptoms can be seen from novel treatment approaches, this Research Topic also highlights the need for continued monitoring of patients undergoing psychotropic treatment.
Author contributions
PDC: Writing – original draft. MS: Writing – review & editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Kessler RC, Chiu WT, Hwang IH, Puac-Polanco V, Sampson NA, Ziobrowski HN, et al. Changes in prevalence of mental illness among US adults during compared with before the COVID-19 pandemic. Psychiatr Clinics North America. (2022) 45:1–28. doi: 10.1016/j.psc.2021.11.013
2. McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. (2023) 22:394–412. doi: 10.1002/wps.21120
3. Stuhec M and Di Ciano P. Editorial: Case reports in psychopharmacology, volume II. Front Psychiatry. (2025) 16:1554037. doi: 10.3389/fpsyt.2025.1554037
4. Stuhec M and Di Ciano P. Editorial: Case reports in psychopharmacology. Front Psychiatry. (2024) 15:1364711. doi: 10.3389/fpsyt.2024.1364711
5. Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, et al. Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry. (2025) 82:395–405. doi: 10.1001/jamapsychiatry.2024.4789
6. Stuhec M. Medication reconciliation and seamless care led by clinical pharmacists in Slovenia: a national reimbursed program ensuring safe and effective transition of care. Int J Clin Pharm. (2025) 47:239–46. doi: 10.1007/s11096-024-01840-9
7. Doherty AM, Kelly JF, McDonald C, O’Dwyer AM, Keane J, and Cooney J. A review of the interplay between tuberculosis and mental health. Gen Hosp Psychiatry. (2013) 35:398–406. doi: 10.1016/j.genhosppsych.2013.03.018
8. Fornaro M, Carvalho AF, De Prisco M, Mondin AM, Billeci M, Selby P, et al. The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. Neurosci Biobehav Rev. (2022) 132:289–303. doi: 10.1016/j.neubiorev.2021.11.039
Keywords: schizophrenia, mental illness, adverse events, psychopharmacology, pharmacogenetics, antipsychotics, GLP-1 agonist
Citation: Stuhec M and Di Ciano P (2025) Editorial: Case reports in psychopharmacology, volume III. Front. Psychiatry 16:1721565. doi: 10.3389/fpsyt.2025.1721565
Received: 09 October 2025; Accepted: 06 November 2025; Revised: 06 November 2025;
Published: 17 November 2025.
Edited and reviewed by:
Octavian Vasiliu, Dr. Carol Davila University Emergency Military Central Hospital, RomaniaCopyright © 2025 Stuhec and Di Ciano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Patricia Di Ciano, cGF0cmljaWEuZGljaWFub0BjYW1oLmNh